Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sidney Reilly who wrote (5612)	11/2/1998 12:05:00 AM
From: margie	Read Replies (2) of 6136

Boehringer Ingelheim is based in Ingelheim, Germany and is a privately-held company. Roxane Laboratories is a subsidiary of Boehringer I. boehringer-ingelheim.com Boehringer Ingelheim's anti-HIV drug nevirapine (Viramune was granted a conditional Notice of Compliance on September 3, 1998 by Canada's Health Protection Branch (HPB) Pharmacia and Upjohn's anti-HIV drug, delavirdine (Rescriptor) was granted conditional approval by the HPB on July 22, 1998. Agouron's anti-HIV drug, nelfinavir (Viracept) was granted unconditional approval by the HPB on August 11 1998. Interesting that both Viramune and Rescriptor were given conditional approval in Canada , and Viracept was given unconditional approval. catie.ca What's New- Canada Like Sustiva, Viramune is a moderate P450 inducer and lowers the levels of most protease inhibitors. Levels of Viracept are not changed, when combined with Viramune. Viramune's dose is one tablet twice a day. Delavirdine dose is four pills, three times a day. Delavirdine usually boosts the amount of protease inhibitors. Try search.com for any search

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next